Non-IgE-mediated drug-induced hypersensitivity reactions in pediatrics
- 19 August 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Pediatrics
- Vol. 36 (6) , 674-683
Abstract
Purpose of review: Despite their prevalence and potential severity, non-IgE-mediated drug-induced hypersensitivity reactions (DHRs) are under-researched and poorly defined, particularly in children. Presentations range from mild cutaneous reactions to severe systemic diseases, with pathophysiological mechanisms and reliable diagnostic markers not well established. The lack of validated tests often leads to permanent drug restrictions, reliance on second-line drugs, and increased costs. Focusing on recent advancements and areas needing further research, this review aims to enhance children's recognition, diagnosis, and management of non-IgE-mediated DHRs. Recent findings: Recent studies have enhanced the understanding of immediate and delayed non-IgE-mediated drug reactions. Key findings include the Mas-related G protein-coupled receptor X2 in mast cells and the identification of HLA alleles linked to severe cutaneous adverse reactions, such as Stevens–Johnson syndrome and toxic epidermal necrolysis. Improved diagnostic techniques, including skin testing, show promise in identifying immediate and delayed non-IgE DHRs. Additionally, research highlights the impact of cofactors, drug metabolites, and co-infections on these DHRs and explores potential biomarkers for predicting reaction severity. Summary: Non-IgE-mediated DHRs are a significant cause of morbidity and treatment changes in pediatric patients. Recent research underscores their clinical presentations and mechanisms, paving the way for more precise diagnostic and therapeutic strategies to improve patient outcomes.Keywords
This publication has 79 references indexed in Scilit:
- Use of the Electronic Health Record for Monitoring Adverse Drug ReactionsCurrent Allergy and Asthma Reports, 2023
- Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisJAMA Dermatology, 2023
- Recent Updates in Understanding NSAID HypersensitivityCurrent Allergy and Asthma Reports, 2023
- Delabeling penicillin allergy in a pediatric primary care clinicAnnals of Allergy, Asthma & Immunology, 2023
- Adverse Reactions to Biologic Medications Used in Allergy and Immunology DiseasesCurrent Allergy and Asthma Reports, 2022
- Confirmation of drug allergy in a general pediatrics outpatient clinicAnnals of Allergy, Asthma & Immunology, 2022
- Quality Improvement to Engage General Pediatrics in Reducing Inaccurate Penicillin Allergy LabelsAcademic Pediatrics, 2022
- Road Less Traveled: Drug Hypersensitivity to Fluoroquinolones, Vancomycin, Tetracyclines, and MacrolidesClinical Reviews in Allergy & Immunology, 2022
- Race and Pharmacogenomics—Personalized Medicine or Misguided Practice?JAMA, 2021
- Frequency of self-reported drug allergyAnnals of Allergy, Asthma & Immunology, 2017